Burseraceae · oleogum resin
Indian frankincense
Boswellia serrata
Shallaki resin mapped to human joint-pain and selected GI-inflammation trials of AKBA-standardized extracts.
Safety first
Resin extracts appear in human osteoarthritis and some inflammatory-bowel trials. GI upset is common. Not interchangeable with African Boswellia liturgical frankincense.
Tradition vs trials
Traditional record. API records shallaki for sandhigata-type joint complaints and related inflammatory patterns.
Trial literature. RCTs in osteoarthritis and some IBD-type settings report symptom-scale changes. Sample sizes are modest; extracts differ in AKBA content.
Practical ranges
Educational ranges — not a prescription. Culinary use is not an extract.
resin extract
Joint trials often use about 300–400 mg of a concentrated extract two to three times daily; AKBA percentages vary by product
Ayurvedic Pharmacopoeia of India (API) — Educational range only — not a prescription. A licensed clinician individualizes product, dose, and duration.
Pregnancy, nursing, children
- Pregnancy. Insufficient reliable data; avoid unless a clinician directs otherwise.
- Nursing. Insufficient reliable data; avoid unless a clinician directs otherwise.
- Children. Insufficient reliable data; avoid unless a clinician directs otherwise.
Contraindications
- known Burseraceae resin allergy
- active peptic symptoms that worsen on resin extracts
Key interactions
- anti-inflammatories · note
Pharmacodynamic overlap is theoretical; GI stacking is the practical issue.